Pfizer: positive results in colorectal cancer

(CercleFinance.com) - Pfizer announced Monday the publication of positive results from a phase 3 study evaluating its small molecule Braftovi in the treatment of patients with metastatic colorectal cancer.


The study showed that Braftovi combined with Merck's Erbitux and Folfox chemotherapy delivered a statistically significant and clinically relevant improvement in overall survival and progression-free survival in patients with BRAF V600 mutations, compared with chemotherapy alone or with Roche's Avastin.

On the basis of these data, Pfizer says it will share the trial's findings with the US FDA with a view to future approval of the product in this indication.


Copyright (c) 2025 CercleFinance.com. All rights reserved.